Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157659 | 0.82 | CYP1A2 (0.61) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL29297658 | 0.82 | RAB9A (0.57) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL29812491 | 0.82 | CYP1A2 (0.61) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL23877213 | 0.81 | POLB (0.53) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL29296649 | 0.80 | POLB (0.51) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL27044923 | 0.78 | HSD17B10 (0.62) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL27044925 | 0.78 | NOTUM (0.50) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL27044922 | 0.78 | CYP1A2 (0.43) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL6271484 | 0.78 | RAB9A (0.65) | POLBHSD17B10GAARAB9AALDH1A1 | |
| SCHEMBL8705447 | 0.77 | HTR7 (0.49) | POLBHSD17B10RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | STANFORD RES INST INT (US) | 2024-07-11 | — | — | US | disclosed |
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
| EP-0623122-A1 | BENZOPYRAN AND RELATED LTB 4? ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0607217-A1 | PYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993015066-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993007137-A1 | PYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | RNASEH1, RNASEL, DNASE1 | POLB 116/4885HSD17B10 1977/4885GAA 201/4885 |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | POLB 2562/4885HSD17B10 3172/4885GAA 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.